Literatur

 

  1. Hummel et al. 2019 Physiologic and histopathologic effects of targeted lung denervation in an animal model J Appl Physiol 126:67–76
  2. Valipour et al. 2020 Two-year outcomes for the double-blind, randomized, sham-controlled study of targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2 Int J Chron Obstruct Pulmon 15:2807–2816
  3.   Pavord et al. 2017 Mepolizumab for eosinophilic chronic obstructive pulmonary disease N Engl J Med 377(17): 1613–1629
  4.   Mayse et al. 2020 Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures Respir Res 21:117
  5.   Zhang et al. 2018 A systematic review of how patients value COPD outcomes Eur Respir J 19;52(1)
  6.   Ihenacho et al. 2020 Economic burden of chronic obstructive pulmonary disease (COPD): A systematic literature review Int J Chron Obstruct Pulmon Dis 26;15: 439–460
  7.   Dalal et al. 2011 Costs of COPD exacerbations in the emergency department and inpatient setting Respir Med 105(3):454–60
  8.   Dalal et al. 2015 Impact of COPD exacerbation frequency on costs for a managed care population J Manag Care Spec Pharm 21(7): 575–83
  9.   Patel et al. 2018 COPD affects worker productivity and health care costs Int J COPD 13:2301–2311
  10.  Lipson et al. 2018 Once-daily single-inhaler versus dual therapy in patients with COPD N Engl J Med 378(18): 1671–1680
  11.  Rabe et al. 2020 Triple inhaled therapy and two glucocorticoid doses in moderate-to-very severe COPD N Engl J Med 383(1):35–48
  12.  Donaldson et al. 2002 Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57(10):847–52
  13.  Halpin et al. 2017 Effect of a single exacerbation on decline in lung function in COPD Respir Med 128: 85–91 
  14.  Dransfield et al. 2017 Acute exacerbations and lung function loss in smokers with and without Chronic Obstructive Pulmonary Disease Am J Respir Crit Care Med 195(3): 324–330
  15.  Seemungal et al. 1998 Effect of exacerbation on quality of life with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157:1418–22
  16.  Westerik et al. 2017 Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD Respir Res 18(1):31
  17.  Soler-Cataluna et al. 2005 Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60(11):925–31
  18.  Rothnie et al. 2018 Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease Am J Respir Crit Care Med 198(4):464–471
  19.  Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2021 Report
  20.  Hurst et al. 2020 Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life Eur J Intern Med 73:1–6
  21.  Pison et al. 2021 Safety of denervation following targeted lung denervation therapy for COPD AIRFLOW-1 3-year outcomes Respir Res 22(1): 62
  22.  Hartman JE, Conway F, Degano B, Augustijn SWS, Herth FJF, Mayr A, Chacaroun S, Tonkin J, Valipour A, Slebos DJ. Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD. Respir Med 2021; 188: 106604.
  23.  Khakban et al. 2017 The projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective Am J Respir Crit Care Med 2016;195(3):1–5.
  24.  Canning BJ 2006 Reflex regulation of airway smooth muscle tone J Appl Physiol 101:971–985. 
  25.  Valipour A et al. 2018 Long-term safety of bilateral targeted lung denervation in patients with COPD Int J Chron Obstruct Pulmon Dis 13:2163–2172.
  26.  Valipour A et al. 2019 Safety and dose study of targeted lung denervation in moderate/severe COPD patients Respiration 98:329–339. 
  27.  Slebos DJ et al. 2019 Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial Am J Respir Crit Care 200:1477–1486.

 

Zu häufigen potenziellen Risiken im Zusammenhang mit dem TLD-Verfahren zählen u. a. Verschlimmerung der COPD-Symptome (Kurzatmigkeit, vermehrtes Husten, COPD-Exazerbationen), Abhusten von blutigem Schleim, Schluckbeschwerden, Schmerzen in der Brust, Magenverstimmung oder Völlegefühl, Verdauungsstörungen und Fieber. 

 

Das dNerva®-Lungendenervierungssystem ist ein Prüfprodukt in den USA und besitzt die CE-Kennzeichnung.